Godrej Consumer Products - Initiating Coverage Report

GCPL reported robust conso revenue growth of 18.3% led by 9% volume growth, while India business revenue grew 12.0% led by 7.0% volume growth. Growth was led by strong performance in home care (12%) & personal care (11%), along with strong recovery in Indonesia (15%) and GUAM (47%). However, India business volume growth impacted by a weak June for HI due to an unfavorable base. The management indicated that India volume growth of 7% in Q1FY27 was at the lower end of the expected range, with growth likely to improve in the coming quarters as HI volumes recover. GM contracted to 48.1% due to higher LPG, kerosene and Labsa costs, while EBITDAM declined only 50bps YoY to 19.0%, supported by lower ad, employee and other expenses. Against 9% input cost inflation, the company took a 5% price hike in Q1, with a similar hike expected in Q2. India EBITDA growth is expected to remain in high-single to double digits, while standalone margins are likely to recover to the 24–26% normative range, with stronger recovery expected in H2 led by pricing and operating efficiency. We remain constructive on GCPL, supported by improving India execution, stabilizing Indonesia and strong growth in GAUM. Sustained demand, innovation and market share gains should drive growth, though higher input costs may weigh on margins. We initiate coverage with a ‘Buy’ rating, valuing the stock at 45x FY28E EPS to arrive at a TP of Rs 1,222.

Godrej Consumer Products Ltd. Stock Price Chart

Q1FY27 Performance:

Revenue and EBITDA in line, while APAT below consensus estimates: Net sales grew 18.3% YoY to Rs 42.3bn led by 9% UVG. India business sales grew 12% YoY with 7% volume growth. GM contracted by 260bps YoY to 48.1%. A 260bps increase in RM cost was partially offset by 40/110/70bps decline in ad spends/employee exp/other exp, respectively. Consequently, EBITDAM contracted by 50bps YoY to 19.0%. EBITDA grew by 15.4% YoY to Rs 8.0bn. APAT grew by 10.2% YoY to Rs 5.2bn.

Category-wise Performance & Outlook:

Home Care revenue grew 12% YoY, led by improving HI, strong momentum in air fresheners and fabric care, and rapid scaling of incense sticks, supported by innovation and MS gains. Personal Care revenue grew 11%, driven by skin cleansing, hair colour and perfumes & deodorants, aided by premiumisation, liquid-format adoption and new launches. Soap volumes turned positive after a prolonged weakness, with the company expecting early-single-digit growth in the near-term and gradual acceleration thereafter. Internationally, Africa, USA & Middle East grew 47% YoY, while Indonesia grew 15% with 10% UVG, supported by strong FMCG, air care and HC performance. The company expects Africa to deliver mid-to-high teens CC growth in FY27E, while Indonesia should benefit from favourable El Niño conditions. In India, a drier monsoon could weigh on HI in the near term, although a warmer winter may support recovery in H2.

Outlook:

We expect GCPL to sustain healthy medium-term growth, supported by improving domestic demand, premiumisation, innovation and strong HC/PC momentum. Increasing rural demand, cost efficiencies and operating leverage should drive volume and margin recovery, while international markets provide further growth diversification.

Valuation:

We forecast a Revenue/EBITDA/PAT CAGR of 10.0%/10.2%/9.2% over FY26–FY28E. We initiate with ‘Buy’ rating on GCPL, supported by its strong brands, leadership across key categories, improving execution and healthy earnings trajectory. Premiumisation, innovation and portfolio simplification should drive sustainable growth and margin recovery. We value the stock at 45x FY28E EPS to arrive at a target price of Rs 1,222.

Company website: https://www.godrejcp.com/

Click to download the full Godrej Consumer Products Q1FY27 Review Analysis

Analyst:

• Sachin Bobade - HOR, Institutional Equities
• Akshay Patel - Senior Research Associate, Institutional Equities

Open your MNCL Demat Account

Godrej Consumer Products Q1FY27 Results: Key Questions Answered

Godrej Consumer Products (GCPL) reported consolidated revenue growth of 18.3% YoY in Q1FY27, driven by 9% underlying volume growth and a strong recovery in Indonesia and Africa, USA and the Middle East (GAUM). MNCL Research has initiated coverage on the stock with a Buy rating and a target price of Rs 1,222, implying a 16% upside. The questions below cover quarterly performance, category trends, margin outlook and valuation rationale.

What is the target price for Godrej Consumer Products?

MNCL Research has set a target price of Rs 1,222 for Godrej Consumer Products with a Buy rating. This implies an upside of about 16% and is based on 45x FY28E EPS.

Why does MNCL Research have a Buy rating on GCPL?

The rating is supported by GCPL's strong brands, leadership across key categories, improving execution and a healthy earnings trajectory. Premiumisation, innovation and portfolio simplification are expected to drive sustainable growth and margin recovery.

How did GCPL perform in Q1FY27?

Consolidated net sales grew 18.3% YoY to Rs 42.3bn, led by 9% underlying volume growth. EBITDA rose 15.4% YoY to Rs 8.0bn, while the EBITDA margin contracted 50bps to 19.0%. Adjusted PAT grew 10.2% YoY to Rs 5.2bn, below consensus estimates, while revenue and EBITDA were in line.

How did GCPL's India business perform?

India business revenue grew 12.0% YoY with 7.0% volume growth. Management indicated that 7% volume growth was at the lower end of the expected range, mainly due to a weak June for household insecticides on an unfavourable base. Volume growth is expected to improve in the coming quarters as household insecticide volumes recover.

Which categories drove GCPL's growth?

Home care revenue grew 12% YoY, led by improving household insecticides, strong momentum in air fresheners and fabric care, and rapid scaling of incense sticks. Personal care revenue grew 11%, driven by skin cleansing, hair colour and perfumes and deodorants. Soap volumes turned positive after a prolonged period of weakness.

How did GCPL's international business perform?

Africa, USA and Middle East (GAUM) revenue grew 47% YoY, while Indonesia grew 15% with 10% underlying volume growth. The company expects Africa to deliver mid-to-high teens constant currency growth in FY27E, while Indonesia should benefit from favourable El Niño conditions.

Why did GCPL's gross margin decline in Q1FY27?

Gross margin contracted 260bps YoY to 48.1% due to higher LPG, kerosene and LABSA costs. Lower advertising, employee and other expenses partly offset this, limiting the EBITDA margin decline to 50bps. Against 9% input cost inflation, the company took a 5% price hike in Q1, with a similar hike expected in Q2.

What is the margin outlook for GCPL?

India EBITDA growth is expected to remain in the high-single to double-digit range. Standalone margins are likely to recover to the normative 24% to 26% range, with a stronger recovery expected in H2FY27, led by pricing actions and operating efficiency.

What are the key risks for GCPL?

Higher input costs may continue to weigh on margins in the near term. A drier monsoon could affect household insecticide demand in India, although a warmer winter may support recovery in H2. Execution on pricing and volume recovery remains a key monitorable.

What is the growth outlook for GCPL?

MNCL Research forecasts Revenue, EBITDA and PAT CAGR of 10.0%, 10.2% and 9.2% respectively over FY26 to FY28E. Improving domestic and rural demand, premiumisation, innovation, cost efficiencies and international diversification are expected to support growth.

Before You Trade, Strengthen Your Foundations with These Guides

• For a stronger understanding of indicators such as RSI, VWAP, and trendlines, check our 👉 Technical Analysis Fundamentals section.
• Want to refine your risk-reward planning? Explore our insights on 👉 Position Sizing & Risk Management Strategies.